Century Therapeutics completed the acquisition of Empirica Therapeutics.

Century Therapeutics, a biotechnology company that specializes in developing cell therapy products for the treatment of cancer, completed the acquisition of Empirica Therapeutics, a biotechnology company that focuses on developing novel therapies for the treatment of brain cancer, specifically glioblastoma (GBM). Financial terms were not disclosed. “We are pleased to welcome the Empirica team to the Century family. Their deep expertise and unique capabilities will allow us to accelerate efforts to develop iPSC derived immune effector cell products designed to treat and potentially cure brain cancer.” Lalo Flores, PhD, Century Therapeutics Chief Executive Officer.